Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis

PharmacoEconomics

Volumn 22, Issue 14, 2004, Pages 929-942

  Sullivan, Patrick W ^a   Follin, Sheryl L ^a   Nichol, Michael B ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BUDESONIDE; CORTICOSTEROID;

ALLERGIC RHINITIS; ARTICLE; BAYES THEOREM; CONSTIPATION; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFECT; FATALITY; HEALTH CARE UTILIZATION; HUMAN; INJURY; MICTURITION DISORDER; MONTE CARLO METHOD; OCCUPATIONAL ACCIDENT; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PRODUCTIVITY; PURCHASING; SEDATION; TACHYCARDIA; TRAFFIC ACCIDENT; UNITED STATES; XEROSTOMIA;

ACCIDENTS; ATTITUDE TO HEALTH; BAYES THEOREM; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MODELS, ECONOMIC; MONTE CARLO METHOD; QUESTIONNAIRES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; UNITED STATES;

EID: 6044226621     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422140-00003     Document Type: Article

References (80)

1. Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (6 Pt 2): S805-28
2. United States Bureau of the Census. Statistical abstract of the United States, 2000. Washington, DC: US Dept of Commerce Economics and Statistics Administration Bureau of the Census, 2001
3. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999 Mar; 103 (3 Pt 1): 401-7
4. Crystal-Peters J, Crown WH, Goetzel RZ, et al. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000; 6 (3): 373-8
5. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996 Jul-Aug; 17 (4): 185-9
6. Juniper EF. Quality of life in adults and children with asthma and rhinitis. Allergy 1997 Oct; 52 (10): 971-7
7. Roper Starch. Self-care in the new millennium: Consumer Healthcare Products Association, 2001 [online]. Available from URL: http://www.chpa-info. org/web/press_room/statistics/PDFs/CHPA_Final_Report_revised_03_02.pdf [Accessed 2003, Sep 30]
8. Smith EA. Blame El Nino. Drug Topics 1998; 142: 60
9. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81 (5 Pt 2): 478-518
10. Gaillard AW, Gruisen A, de Jong R. The influence of antihistamines on human performance. Eur J Clin Pharm 1988; 35 (3): 249-53
11. Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 1997; 157 (5): 494-500
12. Witek TJ, Canestrari DA, Miller RD, et al. Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists. Ann Allergy Asthma Immunol 1995; 74 (5): 419-26
13. Kay GG, Quig ME. Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc 2001; 22 (5): 281-3
14. Estelle F, Simons R. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999; 83 (5): 481-8
15. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71 (2): 121-6
16. O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995; 50 (3): 234-42
17. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 2000; 132 (5): 354-63
18. Aso T, Sakai Y. Effect of terfenadine, a novel antihistamine on actual driving performance. Ann Allergy 1989; 62: 250
19. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990; 64 (6): 520-6
20. Gilmore TM, Alexander BH, Mueller BA, et al. Occupational injuries and medication use. Am J Ind Med 1996; 30 (2): 234-9
21. Finkle WD, Adams JL, Greenland S, et al. Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol 2002; 89: 244-50
22. Cockburn IM, Bailit HL, Berndt ER, et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41 (11): 948-53
23. Digest of state alcohol-highway safety related legislation current as of January 1, 1996. Washington, DC: National Highway Traffic Safety Administration, 1996
24. American College of Allergy Asthma and Immunology. Allergy survey fact sheet: Roper ASW. Arlington Heights (IL), 2003
25. Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy 1991; 67 (6): 625-33
26. Alford C, Rombaut N, Jones J. Acute effects of hydroxyzine on nocturnal sleep and sleep tendency the following day: a C-EEG study. Hum Psychopharmacol Clin Exp 1992; 7: 25-35
27. Gold MR, Siegel JE, Russell LB, et al. editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
28. Sullivan PW, Follin SL, Nichol MB. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care 2003 Dec; 12: 1382-95
29. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79 (2): 163-72
30. Dockhorn RJ, Bergner A, Connell JT, et al. Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy 1987; 58 (6): 407-11
31. Druce HM, Thoden WR, Mure P, et al. Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial. J Clin Pharmacol 1998; 38 (4): 382-9
32. Lockey RF, Fox RW. Loratadine (SCH 29851) 10mg OD versus clemastine 1mg BID in the treatment of perennial allergic rhinitis. Immunol Allergy Pract 1989; 11: 10-6
33. Harvey RP, Comer C, Sanders B, et al. Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97 (6): 1233-41
34. Kemp JP, Buckley CE, Gershwin ME, et al. Multicenter, double-blind, placebo-controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis. Ann Allergy 1985; 54 (6): 502-9
35. Brandon ML, Weiner M. Clinical investigation of terfenadine, a non-sedating antihistamine. Ann Allergy 1980; 44 (2): 71-5
36. Melillo G, D'Amato G, Zanussi C, et al. A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergie rhinitis. Arzneimittelforschung 1982; 32 (9a): 1202-3
37. Brostoff J, Lockhart JD. Controlled trial of terfenadine and chlorpheniramine maleate in perennial rhinitis. Postgrad Med J 1982; 58 (681): 422-3
38. Backhouse CI, Brewster BS, Lockhart JD, et al. Terfenadine in allergie rhinitis: a comparative trial of a new antihistamine versus chlorpheniramine and placebo. Practitioner 1982; 226 (1364): 347-51
39. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001; 108 (1 Suppl.): S2-8
40. American College of Allergy Asthma and Immunology. New survey reveals allergies nearly twice as common as believed: afflicting more than one-third of Americans. Public Communications Inc. [online]. Available from URL: http://allergy.μg.edu/news/survey.html [Accessed 2002 Jun 6]
41. Managed Care Measures LLC. Respiratory benchmarks; 2000 [online]. Available from URL: http://www.respiratory-benchmarks.com/rhinitis/data/data. asp?.disease=rhinitis [Accessed 2002, Mar ]
42. Schering-Plough Research Institute. Briefing book. Kenilworth New Jersey April 11 2001 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/ 01/briefing/3737b_15_ schering-plough.pdf [Accessed 2002, Dec ]
43. Drummond MF. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
44. Johansson P-O. Evaluating health risks: an economic approach. Cambridge (England); New York: Cambridge University Press, 1995
45. Thompson MS, Read JL, Liang M. Feasibility of willingness-to-pay measurement in chronic arthritis. Med Decis Making 1984; 4 (2): 195-215
46. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986 Apr; 76 (4): 392-6
47. O'Brien B, Viramontes JL. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making 1994 Jul-Sep; 14 (3): 289-97
48. O'Brien BJ, Novosel S, Torrance G, et al. Assessing the economic value of a new antidepressant: a willingness-to-pay approach. Pharmacoeconomics 1995 Jul; 8 (1): 34-45
49. Chestnut LG, Keller LR, Lambert WE, Rowe RD. Measuring heart patients' willingness to pay for changes in angina symptoms. Med Decis Making 1996 Jan-Mar; 16 (1): 65-77
50. O'Brien BJ, Goeree R, Gafni A, et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care 1998 Mar; 36 (3): 370-84
51. Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 1998 Feb; 80 (2): 189-94
52. Zillich AJ, Blumenschein K, Johannesson M, et al. Assessment of the relationship between measures of disease severity, quality of life, and willingness to pay in asthma. Pharmacoeconomics 2002; 20 (4): 257-65
53. Stavem K. Willingness to pay: a feasible method for assessing treatment benefits in epilepsy? Seizure 1999 Feb; 8 (1): 14-9
54. Voruganti LN, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics 2000 Mar; 17 (3): 273-86
55. O'Brien B, Gafni A. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996 Jul-Sep; 16 (3): 288-99
56. Keith PK, Haddon J, Birch S. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis. Rhinocort Study Group. Ann Allergy Asthma Immunol 2000 Jan; 84 (1): 55-62
57. Du Buske LM. Clinical comparison of histamine H1-receptor antagonist drugs. J Allergy Clin Immunol 1996; 98 (6 Pt 3): S307-18
58. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998 Dec 12; 317 (7173): 1624-9
59. National Highway Traffic Safety Administration. Traffic safety facts 2000. Washington, DC: US Department of Transportation, 2001
60. Simpson H. Polydrug effects and traffic safety. J Alcohol Drugs Driving 1985; 1: 17-44
61. Vinson DC, Mabe N, Leonard LL, et al. Alcohol and injury: a case-crossover study. Arch Fam Med 1995; 4 (6): 505-11
62. National Safety Council. Injury facts. Itasca, (IL):, 2000
63. Terhune KW, Ippolito CA, Hendricks DL, et al. The incidence and role of drugs in fatally injured drivers. Washington, DC: US Department of Transportation, National Highway Traffic Safety Administration, 1992. DOT HS 808 065
64. Cimbura G, Lucas DM, Bennett RC, et al. Incidence and toxicological aspects of drugs detected in 484 fatally injured drivers and pedestrians in Ontario. J Forensic Sci 1982; 27 (4): 855-67
65. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136 (7): 873-83
66. Pierfitte C, Macouillard G, Thicoipe M, et al. Benzodiazepines and hip fractures in elderly people: case-control study. BMJ 2001; 322 (7288): 704-8
67. Oster G, Huse DM, Adams SF, et al. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health 1990; 80 (12): 1467-70
68. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316 (7): 363-9
69. Sorock GS. Falls among the elderly: epidemiology and prevention. Am J Prev Med 1988; 4 (5): 282-8
70. Stevens A, Mulrow C. Drugs affecting postural stability and other risk factors in the hip fracture epidemic: case-control study. Community Med 1989; 11 (1): 27-34
71. Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994; 5 (6): 591-8
72. Sheahan SL, Coons SJ, Robbins CA, et al. Psychoactive medication, alcohol use, and falls among older adults. J Behav Med 1995; 18 (2): 127-40
73. Blincoe L, Seay A, Zaloshnja E. The economic impact of motor vehicle crashes, 2000. Washington, DC: National Highway Traffic Safety Administration, US Department of Transportation, 2002
74. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994 Jul; 73 (1): 35-9
75. Fryback DG, Stout NK, Rosenberg MA. An elementary introduction to bayesian computing using WinBUGS. Int J Technol Assess 2001; 17 (1): 98-113
76. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
77. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002 Jul-Aug; 22 (4): 290-308
78. Drugstore.com [online]. Available from URL: www.drugstore.com. [Accessed 2003 Feb 21]
79. Yelin E, Trupin L, Cisternas M, et al. A national study of medical care expenditures for respiratory conditions. Eur Respir J 2002 Mar; 19 (3): 414-21
80. Cauchon D. Fatalities linked to medication: sedation blamed in traffic deaths. USA Today [online]. Available from URL: http: //www.usatoday.com/life/ health/drugs/Ihdru106.htm [Accessed 2002 Jun 7]